Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122689 | 0.89 | NOS3 (0.45) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL22848993 | 0.87 | NOS3 (0.48) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL14258670 | 0.84 | SLC18A3 (0.38) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL22793894 | 0.84 | GNAO1 (0.47) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL23807033 | 0.82 | NOS3 (0.42) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL4110445 | 0.82 | GNAO1 (0.48) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL24691133 | 0.81 | CYP1A2 (0.42) | NOS3NOS1NOS2KMT2A | |
| SCHEMBL23945263 | 0.81 | NOS3 (0.46) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL23696231 | 0.81 | PIK3CD (0.47) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL13162838 | 0.80 | KDM4E (0.41) | NOS3NOS1NOS2GNAO1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NOS3 3425/4885NOS1 3662/4885NOS2 3629/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | NOS3 3933/4885NOS1 3885/4885NOS2 3868/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | NOS3 3933/4885NOS1 3885/4885NOS2 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.